The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy

Abstract

Gene therapy is the only novel technology that currently offers the prospect of a lasting cure for hemophilia and freedom from the burden of repeated injections. Recent data from a handful of patients who have undergone gene therapy for hemophilia B are very encouraging with a sustained factor IX (FIX) level of 0.05 IU/mL maintained for over 4 years. While this level is above the current usual target trough levels, it falls well short of the level that patients on prophylaxis with longer-acting products can expect. Prophylaxis is also associated with high peak levels, which permits patients to maintain an active lifestyle. A major barrier to widespread adoption of gene therapy is a high seroprevalence of antibodies to adeno-associated virus (AAV) vectors in the general population. Young children would be the best candidates for gene therapy in view of much lower seroprevalence to AAV in infants. A stable level of FIX early in life would prevent the onset of joint bleeds and the development of arthropathy. The recent experience with apolipoprotein tiparvovec (Glybera; uniQure, Amsterdam, the Netherlands) indicates that gene therapy is unlikely to prove to be a cheap therapeutic option. It is also quite possible that other new technologies that do not require viral vectors (such as stem cell therapy) may overtake gene therapy during development and make it redundant.

Keywords

hemophilia - therapy - longer-acting - concentrates - gene therapy

• References

• 1 Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G , et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia 2011; 17 (6) 849-853
• 2 Skinner MW. WFH: closing the global gap—achieving optimal care. Haemophilia 2012; 18 (Suppl. 04) 1-12
• 3 Collins PW, Young G, Knobe K , et al; paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124 (26) 3880-3886
• 4 Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015; 169 (6) 768-776
• 5 Shapiro AD, Ragni MV, Valentino LA , et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119 (3) 666-672
• 6 Powell JS, Pasi KJ, Ragni MV , et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
• 7 Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol 2015; 94 (Suppl. 77) 38-44
• 8 Dodt J, Hubbard AR, Wicks SJ , et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21 (4) 543-549
• 9 Stennicke HR, Kjalke M, Karpf DM , et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121 (11) 2108-2116
• 10 Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005; 105 (12) 4865-4870
• 11 Carmen IH. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001; 3 (4) 425-428
• 12 Hacein-Bey-Abina S, Von Kalle C, Schmidt M , et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302 (5644) 415-419
• 13 Howe SJ, Mansour MR, Schwarzwaelder K , et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118 (9) 3143-3150
• 14 Brimble MA, Reiss UM, Nathwani AC, Davidoff AM. New and improved AAVenues: current status of hemophilia B gene therapy. Expert Opin Biol Ther 2015; 2015: 1-14
• 15 Nathwani AC, Tuddenham EG, Rangarajan S , et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 (25) 2357-2365
• 16 Nathwani AC, Reiss UM, Tuddenham EG , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
• 17 Liu Q, Huang W, Zhang H , et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther 2014; 21 (8) 732-738
• 18 Calcedo R, Morizono H, Wang L , et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011; 18 (9) 1586-1588
• 19 Han X, Ni W. Cost-Effectiveness Analysis of Glybera for the treatment of lipoprotein lipase deficiency. Value Health 2015; 18 (7) A756
• 20 Ylä-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol Ther 2015; 23 (2) 217-218
• 21 Huch M, Gehart H, van Boxtel R , et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 2015; 160 (1–2) 299-312
• 22 Park CY, Kim DH, Son JS , et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 2015; 17 (2) 213-220